Guggenheim analyst Yatin Suneja reiterated a Buy rating and $260.00 price target on Biogen (NASDAQ: BIIB).The analyst commented: "Following CELIA's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments